T cell receptor beta variable 28Genealiases: TCRBV28S1 · TCRBV3S1
Q-omics provides the consensus-scored TRBV28 profile across patient tissues and cancer cell-line models. TRBV28 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRBV28 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TRBV28 RNA expression shows 15,736 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where TRBV28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRBV28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRBV28 survival associations across molecular data types. TRBV28 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRBV28 RNA expression–survival associations across cancer types. High TRBV28 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, UCEC, CESC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRBV28 RNA expression.
This table summarizes TRBV28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRBV28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRBV28 shows lower tumor expression in COAD and LUSC and higher tumor expression in KIRC, STAD, BRCA and THCA. The KIRC box plot shows higher TRBV28 RNA expression in tumor versus normal tissue (log2 FC = +2.728, t-test p < 0.001).
This table shows molecular features associated with TRBV28 in patient tissues and cancer cell lines. In patient samples, TRBV28 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
